(3R)-N-[(2Z)-3-(3,4-dichlorophenyl)-5-(hydroxymethyl)-1,3-thiazol-2(3H)-ylidene]-3-fluoropyrrolidine-1-carboxamide | 1163267-21-7

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: (3R)-N-[(2Z)-3-(3,4-dichlorophenyl)-5-(hydroxymethyl)-1,3-thiazol-2(3H)-ylidene]-3-fluoropyrrolidine-1-carboxamide
• 英文别名: (NZ,3R)-N-[3-(3,4-dichlorophenyl)-5-(hydroxymethyl)-1,3-thiazol-2-ylidene]-3-fluoropyrrolidine-1-carboxamide
• CAS: 1163267-21-7
• 化学式: C₁₅H₁₄Cl₂FN₃O₂S
• 分子量: 390.265
• InChiKey: NFDXBKAJDHJXSL-BEFIFZSESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  81.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Faghih Ramin

  公开号：US20090163470A1

  公开（公告）日：2009-06-25

  The invention relates to novel thiazolylidine urea and amide derivatives that are PAMs of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.

  该发明涉及新型噻唑啉基脲和酰胺衍生物，它们是神经尼古丁受体的阳性变制剂，包括这些衍生物的组合物，制备这类化合物的方法，以及使用这类化合物和组合物的方法。
• COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS
  申请人：Rueter Lynne E.

  公开号：US20090221648A1

  公开（公告）日：2009-09-03

  The present invention relates to compositions for treatment of cognitive deficits. Such compositions can have a nicotinic acetylcholine receptor ligand, of either α4β2 subtype or α7 nicotinic acetylcholine subtype, and a histamine-3 receptor ligand, a method of using the same, and a related article of manufacture. Combinations of such active agents with psychostimulants or monoamine reuptake inhibitors also is contemplated.
• US8383657B2
  申请人：——

  公开号：US8383657B2

  公开（公告）日：2013-02-26
• [EN] COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS<br/>[FR] COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES COGNITIFS
  申请人：ABBOTT LAB

  公开号：WO2009082698A1

  公开（公告）日：2009-07-02

  The present invention relates to compositions for treatment of cognitive deficits. Such compositions can have a nicotinic acetylcholine receptor ligand, of either α4ß2 subtype or α7 nicotinic acetylcholine subtype, and a histamine-3 receptor ligand, a method of using the same, and a related article of manufacture. Combinations of such active agents with psychostimulants or monoamine reuptake inhibitors also is contemplated.